Early detection of prostate cancer local recurrence by urinary prostate-specific antigen

Stéphane Bolduc, MD;* Brant A. Inman, MD;† Louis Lacombe, MD;* Yves Fradet, MD;*
Roland R. Tremblay, MD, PhD†

Abstract

Purpose: We assessed the role of urinary prostate-specific antigen (uPSA) in the follow-up of prostate cancer after retropubic radical prostatectomy (RRP) for the early detection of local recurrences.

Methods: We recruited 50 patients previously treated for prostate cancer with RRP and who had not experienced a prostate-specific antigen (PSA) recurrence within their first postoperative year into a cross-sectional laboratory assessment and prospective 6-year longitudinal follow-up study. We defined biochemical failure as a serum PSA (sPSA) of 0.3 μg/L or greater. Patients provided blood samples and a 50-mL sample of first-voided urine. We performed Wilcoxon rank-sum and Fisher exact tests for statistical analysis.

Results: The median sPSA was 0.13 μg/L. The median uPSA was 0.8 μg/L, and was not significantly different when comparing Gleason scores or pathological stages. Of the 50 patients, 27 initially had a nondetectable sPSA but a detectable uPSA, and 11 patients experienced sPSA failure after 6 years. Six patients had detectable sPSA and uPSA initially. Fifteen patients were negative for both sPSA and uPSA, and 13 remained sPSA-free after 6 years. The odds ratio (OR) of having sPSA failure given a positive uPSA test was 4.5 if sPSA was undetectable, but was reduced to 2.6 if sPSA was detectable. The pooled Mantel–Haenszel OR of 4.2 suggested that a detectable uPSA quadrupled the risk of recurrence, independent of whether sPSA was elevated or not. The sensitivity of uPSA for detecting future sPSA recurrences was 81% and specificity was 45%.

Conclusion: Urinary PSA could contribute to an early detection of local recurrences of prostate cancer after a radical prostatectomy.

Introduction

In the past 10 years, emotional debates about new markers of prostate function and pathology have flooded the urological literature and stimulated investigators to deepen their knowledge about kallikreins and other prostate-derived molecules. Serum prostate-specific antigen (sPSA) has proved to be a useful marker in the diagnosis and management of prostate cancer. Graves and colleagues1 demonstrated that not only was prostate-specific antigen (PSA) found in the serum, but that it was also detectable in the urine, an
observation that thus far has not received much attention. Urinary PSA (uPSA) has not been carefully examined as a marker of prostate cancer.

It has been hypothesized that uPSA might prove to be a useful monitor of local tumour recurrence after radical retropubic prostatectomy (RRP). Yet, there is no broad consensus among investigators about the particular role for uPSA, suggesting that heterogeneous methodology and technical issues may bias the results of uPSA studies. The method of collection of urine samples has varied considerably among studies, with specimens obtained before and after prostate massage, in first-voided specimens, in midstream samples and in 24-hour collections. It is quite likely that differences in study methodology are contributing to contradictory results.

To differentiate post-RRP local recurrences from metastatic disease, it is helpful to examine tumour pathology and PSA dynamics. Several parameters, including the timing of PSA failure, PSA doubling time and PSA velocity may give clues as to the nature of the recurrence. None of these measures is wholly accurate, and potentially curable local recurrences can be misdiagnosed as metastatic disease and vice versa.

After RRP, small amounts of uPSA are sometimes detectable and may be the product of androgen-sensitive glandular elements lining the urethra. Consequently, any patient who is androgen-deprived should not have a detectable uPSA. In fact, it has been suggested that one should seriously consider the possibility of a local cancer recurrence if the uPSA is elevated, rising rapidly, or if it is detectable in an androgen-deprived patient. The specific detection of a local recurrence may allow the application of effective local salvage therapy such as radiotherapy, which reduces the probability of progression to metastatic disease. The aim of the present study was to assess whether uPSA is capable of accurately detecting tumour recurrences after RRP.

**Methods**

**Patient selection**

We recruited a group of 50 men previously treated for prostate cancer with RRP who had not experienced an sPSA recurrence within their first postoperative year to participate in our study. We recruited patients consecutively during urological oncology clinical sessions in 2000. During these routine clinical visits, we conducted a cross-sectional laboratory assessment of the consenting men with a planned prospective 1-year longitudinal follow-up period and a primary outcome of biochemical failure (defined as a single sPSA ≥ 0.3 μg/L). Since the initial event-rate was lower than expected, we extended the study follow-up period by 5 years. Owing to potential interference with the uPSA test, we treated patients with active urinary tract infections and then reassessed them at a later date. We obtained approval from our institutional review board and written informed consent from all participants.

**Laboratory assessment**

Patients provided blood samples for the measurement of sPSA and bioavailable testosterone (BT). We measured BT to determine the active androgen level of every patient so that any biasing effect of androgen level on uPSA results could be assessed. We assayed BT using the ammonium sulfate radioimmunoassay method described by Tremblay and Dubé, whereas we measured sPSA using the Hybritech assay.

We measured uPSA in a 50-mL urine sample obtained without restriction on time of day. Since preliminary testing performed on participants with normal or hyperplastic prostate suggested that uPSA levels were optimally...
detected from 1 to 6 hours after the previous void and could be falsely elevated by sexual activity or prostatic massage, we obtained all urine samples after a minimum 1-hour period after the previous void, after a 24-hour period of sexual abstinence and before digital rectal examination. We stored urine samples at –20°C until assayed. We measured uPSA levels using a sandwich enzyme-linked immunosorbent assay (ELISA) method with a polyclonal capture antibody (Poly PSA) and a monoclonal detection antibody 4D1 (developed in laboratory by R.R.T.). Readings occurred in a spectrophotometer at 414 nm. The method has a detection limit of 0.3 μg/L and intra- and interassay coefficients of variation of less than 4%. We blinded patients and their urologists from uPSA results to ensure that patient management decisions were not influenced by the uPSA results.

Statistical methods

We performed statistical analyses using R 2.5.0 (R Foundation for Statistical Computing).15 We compared the distributions of continuous and categorical variables using the Wilcoxon rank-sum test and Fisher exact test, respectively. We measured the association of positive uPSA tests with future biochemical failure with odds ratios (ORs) using the Yates method of zero cell adjustment. We stratified the ORs by sPSA category at baseline (detectable v. undetectable), and we calculated a pooled OR using the Mantel–Haenszel method.16 We constructed univariate Cox models to determine which clinical factors predicted biochemical failure. All p values were 2-sided and we considered them to be statistically significant at p ≤ 0.05.

Results

The clinical characteristics of the patient cohort are detailed in Table 1. Briefly, the median patient age was 64.5 years and the median time from RRP to last follow-up was 7.6 years. Though most patients had an undetectable sPSA at baseline, 8 (16%) had a detectable sPSA that had not yet reached our failure limit of 0.3 μg/L. Biochemical failure eventually occurred in 21 patients (42%), 9 in whom metastases later developed. Univariate Cox models showed that T3 tumour stage (hazard ratio [HR] 4.4, 95% confidence interval [CI] 1.7–11.2, p = 0.001), positive lymph nodes (HR 6.5, 95% CI 2.4–17.5, p = 0.001), and Gleason score (HR 1.5, 95% CI 1.2–1.9, p = 0.002) predicted biochemical failure, whereas serum BT (HR 1.2, 95% CI 0.8–2.0, p = 0.41) and patient age (HR 1.0, 95% CI 0.9–1.1, p = 0.88) did not. Two patients died from a different cancer and 11 were lost to follow-up after 5 years.

Of the 50 patients in the study, 27 had undetectable sPSA at baseline, whereas their uPSA levels were detectable. Of these, 11 (41%) eventually experienced a sPSA failure and received treatment: 2 of 2 responded to radiotherapy, 4 of 4 responded to androgen deprivation therapy (ADT) and 5 are currently stable and under active surveillance. A total of 15 patients had undetectable sPSA and uPSA at baseline, 2 of whom experienced prostate cancer recurrence (1 responded to radiotherapy, 1 responded to ADT). Six patients had a detectable sPSA and uPSA at baseline (4 of 5 responded to radiotherapy, 1 of 5 failed radiotherapy and received ADT, and 1 received ADT). Lastly, 2 patients had a detectable sPSA with an undetectable uPSA at baseline and received ADT.

At baseline, 33 patients (66%) had a detectable uPSA, 17 of whom (52%) went on to experience prostate cancer recurrence over the following 5 years. We found that no factor, including tumour stage, presence of positive lymph nodes, tumour grade, serum BT, sPSA and patient age affected uPSA levels (Table 2). In fact, the only thing that seemed to affect uPSA levels was recurrent prostate

<table>
<thead>
<tr>
<th>Variable</th>
<th>Undetectable uPSA, n = 17</th>
<th>Detectable uPSA, n = 33</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median, yr (IQR)</td>
<td>64 (62–66)</td>
<td>68 (60–72)</td>
<td>0.11†</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1A/B</td>
<td>1 (6)</td>
<td>2 (6)</td>
<td>0.79‡</td>
</tr>
<tr>
<td>T2</td>
<td>10 (59)</td>
<td>15 (45)</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>6 (35)</td>
<td>16 (48)</td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>16 (94)</td>
<td>28 (85)</td>
<td>0.79‡</td>
</tr>
<tr>
<td>N1/2</td>
<td>1 (6)</td>
<td>5 (15)</td>
<td></td>
</tr>
<tr>
<td>Gleason score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>11 (65)</td>
<td>25 (76)</td>
<td>0.54‡</td>
</tr>
<tr>
<td>7</td>
<td>3 (18)</td>
<td>2 (6)</td>
<td></td>
</tr>
<tr>
<td>8–10</td>
<td>3 (18)</td>
<td>6 (18)</td>
<td></td>
</tr>
<tr>
<td>Serum testosterone, nmol/L (IQR)</td>
<td>1.0 (0.5–1.6)</td>
<td>1.0 (0.8–1.6)</td>
<td>0.39†</td>
</tr>
<tr>
<td>Serum PSA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median, mg/L (IQR)</td>
<td>0 (0–0)</td>
<td>0 (0–0)</td>
<td>0.39†</td>
</tr>
<tr>
<td>&gt; 0</td>
<td>2 (12)</td>
<td>6 (18)</td>
<td></td>
</tr>
<tr>
<td>PSA recurrence</td>
<td>4 (24)</td>
<td>17 (52)</td>
<td>0.08†</td>
</tr>
</tbody>
</table>

IQR = interquartile range; PSA = prostatic-specific antigen; TNM = tumour, nodes, metastases; uPSA = urinary prostatic-specific antigen.

*Unless otherwise indicated.
†Wilcoxon rank-sum test.
‡Fisher exact test.
cancer. The 5- and 10-year sPSA recurrence-free survival rates of patients with detectable uPSA were 81% (95% CI 63–91) and 41% (95% CI 22–60), respectively (Fig. 1). In contrast, the 5- and 10-year sPSA recurrence-free survival rates with undetectable uPSAs were both 77% (95% CI 49–90), indicating a divergence in survival occurring at roughly 5 years postoperatively.

When we evaluated uPSA for its association with sPSA recurrence, we noted that the strength of association depended on sPSA level. This is demonstrated in Table 3, where it is shown that the odds of having an sPSA failure given a positive uPSA test was 4.5 if sPSA was undetectable, but was reduced to 2.6 if sPSA was detectable. The pooled Mantel–Haenszel OR of 4.21 (95% CI 0.89–19.77, p = 0.12) suggested that having a detectable uPSA quadrupled the risk of recurrence, independent of whether sPSA was elevated or not. Overall, the sensitivity of uPSA for detecting future sPSA recurrences was 81% and its specificity was 45%. With the observed prevalence of sPSA recurrence of 42%, the positive predictive value of the uPSA test was 52% and its negative predictive value was 76%. The positive and negative diagnostic ORs were 1.47 and 0.42, respectively.

**Discussion**

After the treatment of prostate cancer, a thorough and careful follow-up regimen must be ensured to detect cancer that has escaped initial treatment. At the present time, sPSA is the best tool we have to detect recurrent prostate cancer, regardless of whether the recurrence is confined to the prostatic fossa or metastatic in nature. In the present study, we assessed uPSA as a complementary method to detect recurrent prostate cancer after RRP. Based on previously published data,17 we hypothesized that uPSA might rise before sPSA and therefore provide an opportunity to initiate salvage treatment while the disease burden was still relatively low. Second, we felt that uPSA might be useful to distinguish cancer recurrences localized to the prostatic fossa from those that were metastatic. From previous work in our laboratory on the PSA physiology, we can add that the presence of PSA in the urine has to be by local secretion into the urethral lumen. In fact, PSA should not be found in the urine by glomerular filtration from a distant metastasis because the glomerulus does not normally allow the passage of proteins of the size and charge of PSA. Therefore, a local or regional recurrence not draining into the urethra (e.g., invasion of a regional lymph node) could lead to sPSA failure but not to uPSA detection. This distinction is clinically important because the treatment of a metastatic recurrence is very different from that of a local recurrence. Interestingly, among the patients with detectable uPSA and who presented sPSA failure, 6 of 7 responded to radiotherapy and also lowered their uPSA. All patients who received ADT saw their uPSA become undetectable. Undetectable uPSA associated with a significant decrease in BT was the main observation in a group of 38 patients receiving ADT (data not shown), confirming that production of uPSA by periurethral glands is under androgen control.7 This observation could explain why 16 patients with detectable uPSA had sPSA that was still undetectable after 6 years; they had normal androgen levels with physiologic periurethral gland PSA production but no evidence of disease.
We observed that a positive uPSA test increased the risk of a subsequent biochemical failure by roughly 4 times. More generally, we noted that uPSA elevations detected in the year 2000 appeared to anticipate cancer recurrences that occurred from 2000–2006, a finding that was independent of the sPSA level in 2000. This suggests that uPSA may be a way of detecting recurrences in patients whose sPSA is low or normal, potentially years before prostate cancer recurrence would have otherwise been diagnosed. However, because of the small sample size in our study, the confidence limits for this OR span 1, indicating a result that is not statistically significant. Despite this, our data suggest that uPSA might be a promising new approach to screen for prostate cancer recurrences, a test that would cost very little to confirm in future studies given that it represents a minor adaptation of existing sPSA diagnostic technology. The next step would be a rigorous prospective trial involving more patients and comparing longitudinal (i.e., consecutive postop) sPSA measurements with longitudinal uPSA measurements.

Another important finding of our study was that uPSA levels were not dependent on the physiological levels of BT, patient age, or other factors that could have potentially altered test performance. This suggests that uPSA might be a diagnostic test that is relatively robust with respect to the variability commonly observed among and within patients, though more work is needed to prove this.

Conclusion

Urinary PSA could contribute to an early detection of local recurrences of prostate cancer after a radical prostatectomy. This clinically important distinction would allow the use of local therapy instead of systemic ADT. Larger prospective longitudinal studies are needed to determine whether uPSA testing is a clinically valid method of detecting local recurrences of prostate cancer.

From the *Division of Urology, Centre Hospitalier Universitaire de Québec (CHUQ), Université Laval, Québec, Que. and the †Division of Urology, Duke University Medical Center, Durham, NC

This article has been peer reviewed.

Detecting prostate cancer local recurrence by uPSA

Competing interests: None declared.

References:


Correspondence: Dr. Stéphane Bolduc, Division of Urology, Centre Hospitalier Universitaire de Québec (CHUQ, CHUL), 2705 Boul. Laurier, R-1742, Québec, QC G1V 4G2; fax 418 654-2137; sbolduc_2002@yahoo.ca